由买买提看人间百态

topics

全部话题 - 话题: biegelsen
(共0页)
f******y
发帖数: 830
1
Wells Fargo analyst Larry Biegelsen raised his rating to outperform from
market perform, saying the termination of Abbott’s joint testing program
with closely held Reata Pharmaceuticals on a drug known as bardoxolone
methyl, used to treat kidney disease.
On Thursday, the companies released a statement citing “excess serious
adverse events and mortality” relating to the tests, saying they were
halting the trials and informing the U.S. Food and Drug Administration,
among other regulatory agencies.... 阅读全帖
f****X
发帖数: 64
2
来自主题: Stock版 - 谁研究过AMRN吗?
DNDN的问题很复杂, Matthew Herper的这篇文章很值的参考一下
How many patients actually want to take Provenge, and how many doctors want
to prescribe it?
No one has a good answer.
The new problem facing Provenge, which Dendreon is calling “cost density,”
would certainly explain what went wrong in the quarter. Not only is
Provenge very expensive ($93,000 per patient), but doctors must outlay all
this cost themselves until Medicare or insurance companies pay them back.
David Miller of Biotech Stock Research, a longtime... 阅读全帖
(共0页)